DSS earnings analysis
What we found in DSS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
DSS reported a weak second quarter, with revenue down 32% year over year to $3,604,000, negative gross and operating margins, and diluted EPS of negative $0.48. All four operating segments contracted, while six-month operating cash flow was negative $1,985,000 and free cash flow was approximately negative $2,199,000. Liquidity is the principal concern: cash was $4,068,000 against approximately $39,900,000 of negative working capital, and management stated that substantial doubt remains regarding the company’s ability to continue as a going concern. The filing reports no material changes to the risk factors from the most recent Form 10-K, but unresolved control weaknesses, defaulted debt, and reliance on related-party financing remain significant negatives.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Declined 32% Year Over Year
- Second-quarter revenue was $3,604,000, down 32% from $5,285,000 in the prior-year quarter and approximately 10% below $4,000,000 in Q1 2026. Management attributed the year-over-year decline to weaker existing-customer orders and delayed customer onboarding.
- Margins Remained Deeply Negative
- Gross margin was negative 25.4%, compared with negative 4.7% in Q1 2026 and approximately 100.0% in the prior-year comparable quarter. Operating margin was negative 105.0%, versus negative 126.7% in Q1 2026 and negative 64.8% in Q2 2025.
- EPS Improved Sequentially, Worsened YoY
- Diluted EPS was negative $0.48, compared with negative $0.60 in Q1 2026 but negative $0.24 in Q2 2025. Net loss attributable to DSS common stockholders was $4,789,000 versus $2,152,000 in the prior-year quarter.
- All Operating Segments Contracted
- Product Packaging revenue was $3,274,000, down 24% year over year, while Securities revenue was $321,000, down 67%. Commercial Lending revenue declined to $6,000 from $9,000, and Biotechnology revenue declined to $3,000 from $7,000.
- Operating Cash Flow Turned Negative
- Six-month operating cash flow was negative $1,985,000 versus positive $454,000 in the prior-year period. Capital expenditures were $214,000, producing six-month free cash flow of approximately negative $2,199,000.
- Delayed Orders Create Potential Backlog
- Management stated that new Product Packaging customer onboarding was pushed to the third and fourth quarters of 2026. It also plans to shift Commercial Lending toward inventory and equipment loans and specialized broker-dealer lending.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Going-Concern Doubt
- The filing states that substantial doubt remains about going-concern status: cash was $4,068,000, marketable securities were $2,809,000, and negative working capital was approximately $39,900,000. Management acknowledged that asset sales, additional financing, and expense reductions may not be achieved.
- Defaulted Real Estate Debt
- The LifeCare Agreement was in default and past due, with approximately $38,504,000 of outstanding principal and interest at June 30, 2026, including $8,317,000 of accrued interest. Total current liabilities were $49,242,000 versus current assets of $9,368,000.
- Persistent Operating Losses
- Six-month net loss increased to $11,262,000 from $7,902,000, while operating loss increased to $9,274,000 from $7,151,000. The deterioration occurred despite total costs and expenses declining only 1% to $17,208,000.
- Material Control Weaknesses Persist
- The company’s disclosure controls and procedures remained ineffective as of June 30, 2026 because material weaknesses reported in the 2025 Form 10-K remained unresolved. Management said remediation steps were still being implemented and tested.
- Loan Portfolio Credit Deterioration
- Commercial Lending revenue fell 63% year over year to $6,000 because several loans moved to non-accrual status. The company maintained a loan-loss reserve of approximately $7,478,000, including reserves against multiple defaulted loans.
- Related-Party Financing and Dilution
- The company issued related-party convertible notes with principal amounts of $2,450,000 and $1,000,000 during 2026, alongside warrants for 16,554,055 and 17,777,776 shares, respectively. Common shares outstanding increased to 10,042,518 from 9,092,518 at December 31, 2025.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.48
- Gross margin
- -25.4%
- Operating margin
- -105.0%
- Segment
- Product Packaging: $3,274,000 revenue, down 24% year over year; operating loss was $956,000 versus $560,000.
- Segment
- Securities and Investment Management: $321,000 revenue, down 67% year over year; operating loss was $1,171,000 versus $921,000.
- Segment
- Commercial Lending: $6,000 revenue, down 63% year over year; operating loss was $88,000 versus $300,000.
- Segment
- Biotechnology: $3,000 revenue, down 57% year over year; operating loss was $697,000 versus $1,191,000.
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects several new Product Packaging customers to onboard in the third and fourth quarters of 2026, is pursuing potential asset sales and additional financing, and plans continued reductions in operating expenses and cash burn.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- DSS, Inc. reported a 13% decline in total revenue for Q1 2026, generating approximately $4.33M, down from $4.95M in Q1 2025. Operating losses increased significantly to $5.49M from $3.73M in the previous year. The…
- 10-K · March 31, 2026
- DSS describes a multi-pronged strategy to optimize operations, streamline its portfolio and scale four core businesses (Product Packaging, Biotechnology, Commercial Lending, Securities & Investment Management) with a…
- 10-Q · August 14, 2025
- DSS reported Q2 revenue of $5,285,000, up $1,074,000 (+25.5%) versus Q2 2024 and up modestly versus Q1 2025. Loss per share narrowed to $(0.24) from $(0.66) a year earlier, and operating loss improved to $(3,425,000)…
- 10-Q · May 15, 2025
- Revenue rose to $4,954,000 for the quarter (up $1,083,000 or +28.0% vs $3,871,000 a year ago) driven by printed products and higher rental income, but the company remained unprofitable with a net loss of $5,296,000 and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DSS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever